Comirnaty (tozinameran - Pfizer/BIONTECH) for COVID-19 - living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 prophylaxis (children) meta-analysis
C4591001 (Adolescents 12-25) NCT04368728		RCT	Comirnaty (tozinameran - Pfizer/BIONTECH)	control	COVID-19 prophylaxis (children)	some concern	1134/1130	suggested	suggested 92 % decrease in confirmed Covid-19, from 1st dose with a moderate degree of certainty due to some concern in risk of bias suggested 97 % decrease in symptomatic Covid-19 with a moderate degree of certainty due to some concern in risk of bias
11 studies excluded by filtering options (1 RCT / 10 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 prophylaxis (children) meta-analysis